Physician profile
Thomas P Mills
NPI 1629288279
$1,227.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $91.44 · 2021: $170 · 2022: $371.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.98 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $198.65 | 2021-2022 | |
| Pfizer INC. | $140.24 | 2019 | |
| Boston Scientific Corporation | $117.98 | 2019 | |
| Janssen Biotech, INC. | $116.12 | 2022 | |
| Abbvie INC. | $91.44 | 2020 | |
| Merck Sharp & Dohme LLC | $61.53 | 2021-2022 | |
| Medtronic, INC. | $29.60 | 2021 | |
| Ferring Pharmaceuticals INC. | $28.20 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.93 | 2019 | |
| Ethicon US, LLC | $25.25 | 2019 | |
| Braintree Laboratories, INC. | $17.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.